Grazoprevir

Drug Profile

Grazoprevir

Alternative Names: MK-5172

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antivirals; Carbamates; Carboxylic acids; Cyclopropanes; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 11 Jan 2017 Kanazawa University initiates a biomarker identification clinical trial in Japan (PO) (UMIN000025575)
  • 01 Dec 2016 Merck completes a phase-II trial in Hepatitis C (Combination therapy, Treatment-naive) in Australia, Austria, Canada, Denmark, France, Germany, Israel, Italy, Lithuania, New Zealand, Poland, Puerto Rico, Spain, Sweden, United Kingdom and USA (PO) (NCT02332707; EudraCT2014-003304-73)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top